It has been reported that 15% to 30% of patients with NSCLC harboring activating EGFR mutations have brain metastasis (BM) at diagnosis.1, 2, 3 Because the central nervous system (CNS) has a blood-brain barrier, BM are less effective than other metastatic sites for chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.